Retrospective Analyse of the Clinical Effect of Rituximab in the Treatment of Glomerular Disease
10.3870/j.issn.1004-0781.2024.10.022
- VernacularTitle:回顾性分析利妥昔单抗治疗肾小球疾病临床疗效
- Author:
Huiping YANG
1
;
Chunyan ZHANG
;
Xiaolei REN
;
Lin HUANG
;
Xiaohong ZHANG
Author Information
1. 北京大学人民医院药学部,北京 100044;河北省唐山中心医院药学部,唐山 063008
- Keywords:
Rituximab;
Glomerular diseases;
Clinical effect
- From:
Herald of Medicine
2024;43(10):1663-1667
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the onset time and short-term clinical effect of rituximab(RTX)in the treatment of glomerular diseases.Methods All case data of rituximab used in the treatment of glomerular diseases in a tertiary hospital from January 2021 to December 2022 were extracted for retrospective study.The changes in blood routine,liver function,kidney function,immunity and other related indexes were analyzed after the treatment of RTX and the clinical effect in the short term was observed.Results A total of 52 patients were collected,of which 30 received RTX standardized therapy.During the follow-up period,plasma albumin showed an upward trend,and the 24-hour urine protein and B cell count showed a downward trend.The values of these indexes after 3 months and 6 months after treatment were significantly different from those before treatment,which was statistically significant(P<0.05).The clinical response rates after the first injection,the second injection,the third injection,the fourth injection,3 months later,and 6 months after RTX treatment were 26.92%,36.00%,51.85%,57.69%,76.92% and 81.82%,respectively.No serious adverse effects occurred during the follow-up period.Conclusions RTX can improve 24-hour urine protein,plasma albumin level and B cell count in glomerular-related diseases,stabilize renal functionand have good safety.
